章酶抑制的目标是TP53突变的AML和AML干细胞/原始细胞
Bing Z Carter1, Po Yee Mak1, Muharrem Muftuoglu1
1Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.
Blood
|June 20, 2023
概括
使用PU-H71准表层细胞,有效地杀死TP53突变性急性髓性白血病 (AML) 细胞和干细胞. 这种方法增强了venetoclax的活性,并防止TP53突变AML的耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 血液学 血液学 血液学
背景情况:
- 突变TP53型急性髓性白血病 (AML) 是一个重大的治疗挑战.
- 热冲击蛋白90 (HSP90) 的综合体 - - 章体,对瘤性蛋白质在恶性细胞中的稳定性至关重要,包括突变p53.
- HSP90抑制剂在AML中表现有前途,在TP53-突变AML细胞和干细胞/原始细胞中发现了表皮细胞.
研究的目的:
- 为了研究针对TP53-突变AML的PU-H71向章体的治疗潜力.
- 评估PU-H71对恶性细胞的特异性与健康的造血干细胞和原始细胞.
- 评估PU-H71与venetoclax在TP53突变AML中的协同作用.
主要方法:
- 高通量药物查以识别HSP90抑制剂.
- 在AML和健康的骨髓 (BM) 细胞中检测章体.
- 在TP53-突变AML模型中使用PU-H71的体外和体内研究 (异种移植和患者衍生).
- 对分子标的评估和与venetoclax的联合治疗.
主要成果:
- 通过诱导亡,PU-H71有效地杀死TP53突变的AML细胞和干细胞/祖细胞.
- PU-H71对健康的人类BM CD34+细胞和小鼠血液形成具有最小的毒性.
- PU-H71与venetoclax协同作用,增强细胞杀伤并防止耐药TP53突变克隆的外生.
结论:
- 章酶抑制是一种可行的策略,用于向TP53突变AML及其干细胞/原始细胞.
- 在TP53-突变AML中,PU-H71显示了治疗潜力,与venetoclax具有良好的安全性和协同活性.
- 向章体需要对TP53-突变AML的治疗进行临床评估.
相关概念视频
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
DNA Damage can Stall the Cell Cycle
9.2K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.2K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K


